Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.53 |
| ▸ | BUB1 | O43683 | 1/20 | 0.52 |
| ▸ | PRKACG | P22612 | 1/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.52 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448496 | 0.99 | MAPK14 (0.57) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448734 | 0.90 | MAPK14 (0.56) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448609 | 0.89 | MAPK14 (0.57) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448700 | 0.88 | MAPK14 (0.51) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448689 | 0.88 | MAPK14 (0.52) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448532 | 0.87 | MAPK14 (0.52) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448735 | 0.87 | MAPK14 (0.53) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448605 | 0.83 | MAPK14 (0.61) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20460491 | 0.83 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448729 | 0.82 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20180312462-A1 | BENZAMIDE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-11-01 | — | — | US | disclosed |
| EP-3357916-A1 | BENZAMIDE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357916-A1 | BENZAMIDE DERIVATIVE | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312462-A1 | BENZAMIDE DERIVATIVE | CYP3A5, ABCB1, CYP2D6 | MAPK14 3791/4885CYP2C9 36/4885MAPK11 4212/4885 |
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | MAPK14 3791/4885CYP2C9 36/4885MAPK11 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.